Literature DB >> 23073152

Rational design of a tripartite fusion protein of heparinase I enables one-step affinity purification and real-time activity detection.

Ziliang Huang1, Fengchun Ye, Chong Zhang, Shuo Chen, Yin Chen, Jingjun Wu, Masahiro Togo, Xin-Hui Xing.   

Abstract

Enzymatic degradation of heparin has great potential as an ecological and specific way to produce low molecular weight heparin. However, the commercial use of heparinase I (HepA), one of the most important heparin lyases, has been hampered by low productivity and poor thermostability. Fusion with green fluorescent protein (GFP) or maltose-binding protein (MBP) has shown potential in facilitating the industrial use of HepA. Thus, tripartite fusion of GFP, MBP and HepA would be a promising approach. Therefore, in the present study, the tripartite fusion strategy was systematically studied, mainly focusing on the fusion order and the linker sequence, to obtain a fusion protein offering one-step purification and real-time detection of HepA activity by fluorescence as well as high HepA activity and thermostability. Our results show that fusion order is important for MBP binding affinity and HepA activity, while the linker sequences at domain junctions have significant effects on protein expression level, HepA activity and thermostability as well as GFP fluorescence. The best tripartite fusion was identified as MBP-(EAAAK)(3)-GFP-(GGGGS)(3)-HepA, which shows potential to facilitate the production of HepA and its application in industrial preparation of low molecular weight heparin.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073152     DOI: 10.1016/j.jbiotec.2012.09.016

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  1 in total

1.  Expression and characterization of heparinase II with MBP tag from a novel strain, Raoultella NX-TZ-3-15.

Authors:  Yinyin Li; Yue Lin; Yingzi Jiang; Hafiza Mahreen Mehwish; Muhammad Shahid Riaz Rajoka; Liqing Zhao
Journal:  Arch Microbiol       Date:  2022-08-11       Impact factor: 2.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.